Advanced Search

 

Study ID Status Title Patient Level Data
CXA30007 Completed A Phase III, 12-week, Multicentre, Double-blind, Double-dummy, Randomised, Placebo and Active Comparator-Controlled, Parallel Group study to investigate the Efficacy and Safety of GW406381 1mg, 5mg, 10mg, 25mg and 50mg administered orally once daily, in adults with Osteoarthritis of the knee.
CXA30009 Completed A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg administered orally once daily, in Adults with Rheumatoid Arthritis
DAN106587 Completed A placebo controlled, single blind, randomised study investigating the safety, tolerability and Pharmacokinetics of repeated oral doses of GSK598809 in healthy male and female volunteers for 28 days.
DAN106589 Completed An open label positron emission tomography study in healthy male subjects to investigate brain Dopamine D3 occupancy kinetics, pharmacokinetics and safety of single oral doses of GSK598809, using [11C]-(+)-PHNO as PET ligand.
DAN106593 Completed A randomized, double-bind, placebo controlled, two-way cross-over study to assess the effects of a single dose of GSK598809, a Selective DRD3 Antagonist, in Modulating Nicotine Reward Study Listed on ClinicalStudyDataRequest.com
DAN107606 Completed A placebo-controlled, single-blind, randomised, human volunteer study investigating the tolerability and pharmacokinetics of escalating single oral doses of GSK598809 in smokers
DAN111282 Completed A placebo-controlled, single-blind, randomised, human volunteer study investigating the tolerability and pharmacokinetics of escalating single oral doses (75mg and above) of GSK598809 in otherwise healthy smokers
DAN111283 Completed An open label, randomised, single dose, three-way crossover study to investigate the relative bioavailability of a 100mg capsule compared to four 25mg GSK598809 capsules and the effect of food on the pharmacokinetics of the 100mg capsule in healthy male and female volunteers.
DB1111509 Completed A single centre, randomised, placebo-controlled, four-way cross over study to assess the safety, tolerability, pharmacodynamics and pharmacokinetics of single inhaled doses of GSK233705 and GW642444 as monotherapies and in combination in healthy subjects. Study Listed on ClinicalStudyDataRequest.com
DB1111581 Completed A multicenter, randomized, double-blind, placebo-controlled, parallel-group, 4-week study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of repeat inhaled doses of the combination of GSK233705 and GW642444 administered once-daily in subjects with COPD Study Listed on ClinicalStudyDataRequest.com
DBU107640 Completed A First Time in Human, Blinded, Randomised, Placebo-Controlled, two-cohort Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Single Oral Escalating Doses of GSK618334 in Healthy Male Volunteers
DIX109177 Completed A Single-Blind, Randomized, Placebo Controlled, Ascending Single and Repeat Dose Study with Once Daily Dosing to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK376501 and to Evaluate Food Effects and the Relative Bioavailability of a Tablet Formulation Compared to the Powder for Reconstitution Formulation in Healthy Overweight and Obese Subjects (DIX109177)
DIX109980 Completed Phase I, Randomized, Open-Label, 3 Period Crossover Drug Interaction Study Between Simvastatin and GSK376501 in Healthy Subjects
DIX109981 Completed A Single-Blind, Randomized, Placebo-Controlled, Ascending Single Dose and Repeat Dose Study with Once Daily Dosing To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK376501 in Healthy Overweight and Obese Subjects
DIX110434 Completed A Single-Center, Non-Randomized, Open-Label, Comparative Study to Assess the Utility of Novel Technologies and Biomarkers as Methods for Measuring Human Pharmacodynamic Response to 8 Weeks of Administration of Rosiglitazone Maleate 4mg BID in Healthy Normal or Overweight Controls, Healthy Obese Subjects and Subjects with Type 2 Diabetes Mellitus (T2DM) Study Listed on ClinicalStudyDataRequest.com
DIX110825 Completed A Single Center, Single Sequence, Open-Label, Repeat-Dose Study to Investigate the Effect of GSK376501 on Hepatic Cytochrome P450 Activity in Healthy Adult Subjects
DPB100925 Completed A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of denagliptin, Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus followed by a 12-week Active Treatment Extension Study Listed on ClinicalStudyDataRequest.com
DPB106652 Terminated GW823093 Japan Phase IIa Mono
DPB106653 Completed PK/PD study of GW823093 in Japanese subjects with T2DM: A single-blind, placebo controlled, randomized, multi-dose study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of GW823093C administered orally for 7 days in Japanese subjects with type 2 diabetes
DPB107246 Withdrawn A multi-center, double-blind, parallel-group, randomized, placebo-controlled study to evaluate the efficacy, safety, and tolerability of denagliptin in subjects with type 2 diabetes mellitus
E3870651 Completed A randomised, Two Way Crossover Study to Determine the Time at Which Therapeutic Plasma Concentrations of Paracetamol are Achieved in Two Marketed Formulations
E7411153 Completed An exploratory study to investigate the inflammatory response during a cold sore episode
EBD100729 Terminated A double-blind, placebo-controlled phase I/II study in patients with mild to moderate ulcerative colitis treated with GI-270384X, an oral ICAM-1 and E-selectin inhibitor
EGF 20002 Completed An Open-Label, Multicenter, Single Arm Phase II Study of Oral GW572016 as Single Agent Therapy in Subjects with Advanced or Metastatic Breast Cancer Who Have Progressed While Receiving Herceptin Containing Regimens
EGF10015 Completed A Four-Way Cross-Over Study to Examine the Effects of Lapatinib on the Pharmacokinetics of Orally and Intravenously Administered Midazolam in Cancer Patients

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.